Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
The Fly
Raymond James views Bretisilocin as solid addition to AbbVie’s Neuro pipeline
4d ago
ABBV
Premium
The Fly
AbbVie to acquire Gilgamesh’s bretisilocin program for up to $1.2B
4d ago
ABBV
Premium
The Fly
AbbVie’s upadacitinib achieves endpoint in Phase 3 alopecia areata trial
8d ago
ABBV
Premium
The Fly
AbbVie completes acquisition of Capstan Therapeutics
10d ago
ABBV
Premium
The Fly
AbbVie announces $195M investment to expand API manufacturing in U.S.
17d ago
ABBV
Premium
The Fly
Starbucks upgraded, Shopify downgraded: Wall Street’s top analyst calls
17d ago
AIZ
CMG
Premium
The Fly
AbbVie assumed with an Overweight at Piper Sandler
17d ago
ABBV
Premium
Ratings
AbbVie: Strong Buy Rating Due to Minimal LOE Risks and Growth in Key Segments
17d ago
ABBV
Premium
The Fly
Regenxbio launches program for surabgene lomparvovec in diabetic retinopathy
22d ago
ABBV
RGNX
Premium
The Fly
AbbVie upgraded to Outperform from Neutral at Daiwa
22d ago
ABBV
Premium
Ratings
AbbVie: Balancing Strong Earnings with Humira Challenges and External Risks
24d ago
ABBV
Premium
Company Announcements
AbbVie Shines in Earnings Call with Strong Growth
27d ago
ABBV
Premium
The Fly
AbbVie price target raised to $227 from $216 at Guggenheim
28d ago
ABBV
Premium
The Fly
AbbVie price target raised to $207 from $205 at Evercore ISI
28d ago
ABBV
Premium
The Fly
AbbVie price target raised to $236 from $227 at Raymond James
28d ago
ABBV
Premium
Ratings
AbbVie Receives Buy Rating from Terence Flynn Due to Strong Financial Performance and Growth Potential
28d ago
ABBV
Premium
Ratings
AbbVie: Balancing Strong Performance with Pricing Uncertainties and Valuation Concerns
28d ago
ABBV
Premium
Company Announcements
AbbVie Reports Strong Q2 2025 Financial Results
28d ago
ABBV
Premium
The Fly
Trump posts letters calling on drug company CEOs to lower prices
29d ago
AZN
BMY
Premium
The Fly
AbbVie says ‘fairly insulated’ from any tariff impacts this year
29d ago
ABBV
Premium
The Fly
AbbVie sees Q3 adjusted EPS $3.24-$3.28, consensus $3.24
29d ago
ABBV
Premium
The Fly
AbbVie sees FY25 adjusted gross margin 84% of sales
29d ago
ABBV
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
